



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eric N. Olson

Da-Zhi Wang

Serial No.: 10/029,217

Filed: December 21, 2001

For: METHODS AND COMPOSITIONS
RELATING TO A CARDIAC-SPECIFIC
NUCLEAR REGULATORY FACTOR

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSD:695US/SLH

#7/RW
05:20:02
RECEIVED
PATENT

MAY 16 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
May 8, 2002	
Date	Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10112563/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 8, 2002



5-13-02

1645

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM


DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

RECEIVED

May 8, 2002

MAY 16 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
May 8, 2002	
Date	Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 10/029,217 entitled "METHODS AND COMPOSITIONS RELATING TO A CARDIAC-SPECIFIC NUCLEAR REGULATORY FACTOR" by Eric N. Olson and Da-Zhi Wang*
Our Reference: UTSD:695US

RECEIVED

MAY 16 2002

TECH CENTER 1600/2900


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A2, C1-C14).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10112563/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl.: as noted

25162366.1

Form PTO-1449 (modified)

Atty. Docket No.
UTSD:695US/SLHSerial No.
10/029,217

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Eric N. Olson
Da-Zhi WangFiling Date:
December 21, 2001Group:
1645

RECEIVED

MAY 16 2002

ER 1600/2900

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,792,453	8/11/98	Hammond <i>et al.</i>	424	93.21	6/7/95
	A2	6,100,242	8/8/00	Hammond <i>et al.</i>	514	44	2/27/96

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Edmondson <i>et al.</i> , "Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis," <i>Development</i> , 120:1251-1263, 1994.
	C2	GenBank Accession Number AC005358.
	C3	GenBank Accession Number AI607474.
	C4	GenBank Accession Number AW500597.
	C5	GenBank Accession Number BE311634.
	C6	Hammond <i>et al.</i> , "Adenoviral based in-vivo gene transfer in the pig," <i>Clin. Res.</i> , 42:123A, 1994.
	C7	Harvey, "NK-2 homeobox genes and heart development," <i>Dev. Biol.</i> , 178:203-216, 1996.
	C8	Kodama, <i>et al.</i> , "Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes," <i>Cir. Res.</i> 81:656-663, 1997.
	C9	Leor <i>et al.</i> , "Transplantation of fetal myocardial tissue into the infarcted myocardium of rat," <i>Circulation</i> , 94(Suppl. II):II-332—II-336, 1996.
	C10	Lin <i>et al.</i> , "Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C," <i>Science</i> , 276:1404-1407, 1997.
	C11	Makino <i>et al.</i> , "Cardiomyocytes can be generated from marrow stromal cells in vitro," <i>J. Clin. Invest.</i> , 103:697-705, 1999.

25118395.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
UTSD:695US/SLHSerial No.
10/029,217

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Eric N. Olson
Da-Zhi WangFiling Date:
December 21, 2001Group:
1645U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
*See Page 1***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C12	Molkentin, "Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins," <i>Cell</i> , 83:1125-1136, 1995.
	C13	Pan, <i>et al.</i> , "Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart," <i>Circ. Res.</i> , 81:611-617, 1997.
	C14	Srivastava <i>et al.</i> , "A subclass of bHLH proteins required for cardiac morphogenesis," <i>Science</i> , 270:1995-1999, 1995.

25118395.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)